- Home
- EPIX vs BNR Comparison
EPIX vs BNR Comparison
Compare EPIX & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- BNR
- Stock Information
- Founded
- EPIX 2009
- BNR 2014
- Country
- EPIX Canada
- BNR China
- Employees
- EPIX N/A
- BNR N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- BNR Medical Specialities
- Sector
- EPIX Health Care
- BNR Health Care
- Exchange
- EPIX Nasdaq
- BNR Nasdaq
- Market Cap
- EPIX 76.8M
- BNR 61.7M
- IPO Year
- EPIX N/A
- BNR 2020
- Fundamental
- Price
- EPIX $1.63
- BNR $5.45
- Analyst Decision
- EPIX Hold
- BNR
- Analyst Count
- EPIX 3
- BNR 0
- Target Price
- EPIX $2.00
- BNR N/A
- AVG Volume (30 Days)
- EPIX 172.2K
- BNR 5.0K
- Earning Date
- EPIX 02-11-2025
- BNR 03-27-2025
- Dividend Yield
- EPIX N/A
- BNR N/A
- EPS Growth
- EPIX N/A
- BNR N/A
- EPS
- EPIX N/A
- BNR N/A
- Revenue
- EPIX N/A
- BNR $72,832,704.00
- Revenue This Year
- EPIX N/A
- BNR $52.90
- Revenue Next Year
- EPIX N/A
- BNR $48.35
- P/E Ratio
- EPIX N/A
- BNR N/A
- Revenue Growth
- EPIX N/A
- BNR N/A
- 52 Week Low
- EPIX $1.40
- BNR $2.62
- 52 Week High
- EPIX $9.60
- BNR $8.99
- Technical
- Relative Strength Index (RSI)
- EPIX 40.19
- BNR 41.94
- Support Level
- EPIX $1.62
- BNR $4.90
- Resistance Level
- EPIX $1.70
- BNR $5.78
- Average True Range (ATR)
- EPIX 0.05
- BNR 0.44
- MACD
- EPIX -0.00
- BNR -0.10
- Stochastic Oscillator
- EPIX 20.00
- BNR 35.62
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.